Epithelioid Mesothelioma and Lung Cancer: Biomarker Shows Which is Which
Researchers from Hiroshima University say they have found a nearly foolproof way to tell the difference between epithelioid mesothelioma and lung cancer. This is critical because the prognosis can be very different between the two. They are also treated differently. But epithelioid mesothelioma and lung cancer are similar in many ways. They cause many of the same symptoms. Even their cells look similar under the microscope. This can make it hard for doctors to deliver an accurate and timely diagnosis. If the new findings are right, the biomarker identified by the Hiroshima researchers could be a diagnostic gamechanger. Lung Adenocarcinoma or Pleural Mesothelioma? At first glance, epithelioid mesothelioma and lung cancer seem to be very different. Mesothelioma makes up about … Continue reading Epithelioid Mesothelioma and Lung Cancer: Biomarker Shows Which is Which
Predicting the Risk of Death from Mesothelioma
New research suggests that the risk of death from mesothelioma does not always hinge on disease type or overall health. Researchers in Brazil and at Mayo Clinic have identified some subtle mesothelioma risk factors that only pathologists can see. These factors go beyond the characteristics of the mesothelioma cells themselves. The study shows the environment around the tumor, the number and type of immune system cells at the tumor site, and even how many cells are in the tumor can all impact the risk of death from mesothelioma. Understanding the Risk Factors for Mesothelioma Asbestos exposure causes most cases of mesothelioma. But not everyone who encounters asbestos gets cancer. Genes and certain lifestyle factors may influence whether an exposed person … Continue reading Predicting the Risk of Death from Mesothelioma
PD-L1 Expression and Mesothelioma Prognosis
The largest study yet on PD-L1 expression and mesothelioma prognosis shows that patients with more of this protein in their cells have poorer odds of survival. Programmed death ligand 1 (PD-L1) helps cancer cells evade immune system attack. Other studies have suggested a link between PD-L1 expression and mesothelioma prognosis. But the new meta-analysis performed by two Chinese researchers appears to confirm it with an even bigger data set. Understanding Mesothelioma Prognosis Malignant mesothelioma is an uncommon cancer that typically carries a poor prognosis. Many people diagnosed with mesothelioma lose their lives to the illness within a year. But there are also many exceptions. Some mesothelioma survivors live for decades after a mesothelioma diagnosis. Australian Paul Kraus is an example. … Continue reading PD-L1 Expression and Mesothelioma Prognosis
Mesothelioma and Lung Cancer: These Biomarkers Can Tell the Difference
Researchers in Canada say when it comes to distinguishing between mesothelioma and lung cancer, some proteins are more valuable than others. The team has identified an especially important protein biomarker for mesothelioma. A biomarker is a compound in body fluid or tissue that can act as a signpost for disease. Understanding the value of this particular protein as compared to other biomarkers may improve the testing process for mesothelioma. Pleural mesothelioma and lung cancer share many of the same characteristics. Both affect the lungs and both cause similar symptoms. But they are treated differently. It is not always easy to tell these two cancers apart, even with high-level diagnostic tools. But the biomarker testing completed in Canada may make it … Continue reading Mesothelioma and Lung Cancer: These Biomarkers Can Tell the Difference
Personalized Immunotherapy for Mesothelioma: New Research Sheds Lights
New research conducted by a team of German and Austrian scientists could help make personalized immunotherapy for mesothelioma possible. Mesothelioma is an incurable cancer caused by exposure to asbestos. Immunotherapy is one of the most promising treatment approaches. But immunotherapy drugs like Keytruda do not work for all patients. Scientists do not know exactly why this is. The new study suggests that understanding biomarkers could lead to better outcomes through personalized immunotherapy for mesothelioma. How Does Immunotherapy Work? Immunotherapy is a broad term that means using the patient’s own immune system to fight their cancer. There are many different types of immunotherapy. Some involve stimulating an immune response. Others involve turning off the mechanism that lets mesothelioma cells hide from … Continue reading Personalized Immunotherapy for Mesothelioma: New Research Sheds Lights
Recommendations for People with a Genetic Predisposition for Mesothelioma
Cancer expects from Ohio State University have just released an updated version of their recommendations for people with a genetic predisposition for mesothelioma. These people have an inherited mutation on their BAP1 tumor suppressor gene. This mutation puts them at risk for several different types of cancer, including malignant mesothelioma. It is not possible to prevent cancer in people with this genetic risk factor. But the Ohio State doctors say awareness and screening may help extend the lives of people with a genetic predisposition for mesothelioma. BAP1 Tumor Predisposition Syndrome BAP1 stands for BRCA association protein 1. The BAP1 gene encodes for the BAP1 protein. BAP1 is one of the proteins that helps keep normal cells from turning into cancer … Continue reading Recommendations for People with a Genetic Predisposition for Mesothelioma
Genetics Affect Accuracy of SMRP Test for Mesothelioma
The SMRP test for mesothelioma is a tool doctors use to help diagnose asbestos cancer and plan treatment. But new research suggests that the test is not as useful as it could be due to genetic variability. Slovenian doctors say a person’s genetics influence how much SMRP they produce. Based on their research, they recommend combining the SMRP test for mesothelioma with genetic testing. Their findings suggest the combination method produces a more accurate and useful mesothelioma biomarker. What is the SMRP Test for Mesothelioma? SMRP stands for soluble mesothelin-related peptides. They are produced when proteins found in the mesothelial membranes start to break down. Malignant mesothelioma is one condition that can trigger this breakdown. As a mesothelioma tumor grows … Continue reading Genetics Affect Accuracy of SMRP Test for Mesothelioma
Immunotherapy for Pleural Mesothelioma: Biomarkers Urgently Needed
A new report says biomarkers are urgently needed to determine which patients would benefit from immunotherapy for pleural mesothelioma. Researchers made the statement in a review of immunotherapy drugs in testing for malignant mesothelioma. They say some of these drugs have proven to be more effective than others for asbestos cancer. But a set of biomarkers would go a long way to funneling patients into the right immunotherapy for pleural mesothelioma. The Status of Immunotherapy for Pleural Mesothelioma Immunotherapy is believed to be the most promising up-and-coming cancer treatment. Immunotherapy treatments harness the strength of the body’s own immune response to attack cancer or help other drugs do so. Like other types of cancer, mesothelioma cells have ways of avoiding … Continue reading Immunotherapy for Pleural Mesothelioma: Biomarkers Urgently Needed
Exhaled Breath Analysis: Is it the Future of Mesothelioma Diagnosis?
A new report says there is much for the mesothelioma community to be excited about in the technology known as exhaled breath analysis. Several studies suggest the method is as accurate at identifying mesothelioma as some more invasive tests. Researchers at the University of Leuven in Belgium led the new study. They analyzed six other studies on exhaled breath analysis The goal was to see how accurate the method is for diagnosing mesothelioma and other asbestos diseases. The researchers conclude that things look good for exhaled breath analysis, but there is more to learn. Searching for Signs of Mesothelioma Pleural mesothelioma is an aggressive lung-related cancer caused by exposure to asbestos. It can take decades to develop, but once it … Continue reading Exhaled Breath Analysis: Is it the Future of Mesothelioma Diagnosis?
Protein Biomarker for Mesothelioma Linked to Shorter Survival
An international team of scientists has identified a protein biomarker for mesothelioma that appears to shorten survival. The biomarker is CD70. It belongs to the tumor necrosis factor (TNF) family of proteins. New research suggests that patients who express more of this protein biomarker for mesothelioma have faster-growing tumors that are less likely to respond to treatment. High CD70 levels have been linked with tumor aggression in some other types of cancer. This is the first time they have been linked to malignant pleural mesothelioma survival. CD70 and Mesothelioma Prognosis Pleural mesothelioma is a highly aggressive type of tumor. It grows on the membranes around internal organs. Mesothelioma rarely responds to standard cancer treatments. People diagnosed with pleural mesothelioma are … Continue reading Protein Biomarker for Mesothelioma Linked to Shorter Survival
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!